These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21167635)

  • 1. Is population screening for prostate cancer good or bad?
    Clarke NW
    Eur Urol; 2011 Mar; 59(3):363-4. PubMed ID: 21167635
    [No Abstract]   [Full Text] [Related]  

  • 2. Is prostate cancer screening bad or good? Summary of a debate at the innovation in urology meeting, September 17-19, 2010, Milan, Italy.
    Roobol MJ
    Eur Urol; 2011 Mar; 59(3):359-62. PubMed ID: 21035943
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening for prostate cancer: practical analysis of the ERSPC [corrected] and PLCO trials.
    Djavan B
    Eur Urol; 2011 Mar; 59(3):365-9. PubMed ID: 21159418
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 5. An argument against routine prostate cancer screening.
    Hoffman RM
    Arch Intern Med; 2003 Mar; 163(6):663-5; discussion 665-6. PubMed ID: 12639196
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening for prostate cancer: evidence and perspectives.
    Schröder FH; Wildhagen MF;
    BJU Int; 2001 Nov; 88(8):811-7. PubMed ID: 11736853
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-cancer screening.
    Preston SH
    N Engl J Med; 2009 Jul; 361(2):202-3; author reply 204-6. PubMed ID: 19593850
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for earlier and less frequent prostate cancer screening.
    Carter HB
    Urology; 2001 Nov; 58(5):639-41. PubMed ID: 11711328
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality.
    Smith DP; Banks E; Clements MS; Gardiner RA; Armstrong BK
    Med J Aust; 2009 Aug; 191(4):199-200. PubMed ID: 19705979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
    Boyle P
    Ann Oncol; 1998 Dec; 9(12):1263-4. PubMed ID: 9932152
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on urology--prostate cancer. Screening for prostate cancer: an European view.
    de Silva FC
    Eur J Surg Oncol; 1996 Apr; 22(2):189-91, 196. PubMed ID: 8608840
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
    Giri VN; Hyatt C; Leader A
    J Urol; 2020 Dec; 204(6):1116-1118. PubMed ID: 32926644
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate-cancer screening.
    Catalona WJ
    N Engl J Med; 2009 Jul; 361(2):202; author reply 204-5. PubMed ID: 19587348
    [No Abstract]   [Full Text] [Related]  

  • 15. Informed consent for prostate-specific antigen screening.
    Wilkinson S; Chodak G
    Urology; 2003 Jan; 61(1):2-4. PubMed ID: 12559252
    [No Abstract]   [Full Text] [Related]  

  • 16. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 17. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
    Carroll PH; Mohler JL
    J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informed consent for prostate-specific antigen screening.
    Catalona WJ
    Urology; 2003 Jan; 61(1):17-9. PubMed ID: 12559258
    [No Abstract]   [Full Text] [Related]  

  • 19. Missing the mark on prostate-specific antigen screening.
    Miller DC; Hollenbeck BK
    JAMA; 2011 Dec; 306(24):2719-20. PubMed ID: 22203542
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of publication of US and European prostate cancer screening trials on PSA testing practices.
    Zeliadt SB; Hoffman RM; Etzioni R; Gore JL; Kessler LG; Lin DW
    J Natl Cancer Inst; 2011 Mar; 103(6):520-3. PubMed ID: 21357307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.